NovaBay to Receive Increase in Funding, Support From Alcon

NovaBay Pharmaceuticals, Inc., a clinical stage biopharmaceutical company creating a new class of anti-infectives for treating multi-drug resistant pathogens, announced Thursday that effective immediately, its partner, Alcon Inc. has increased its on-going financial support of the company’s research and development efforts by more than $2 million per year.
CNNMoney